ストックスクリーナーアプリを入手
5.81
4.91%
-0.30
Nuvation Bio Inc (NUVB) 最新ニュース
Does Nuvation Bio (NUVB) Have the Global Scale to Maximize Taletrectinib’s Regulatory Momentum? - Sahm
Nuvation Bio to offer $200M convertible senior notes - MSN
Nuvation Bio Inc. Class A (NUVB) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Nuvation Bio ups convertible notes offering to $287.5M after greenshoe exercise - MSN
NUVB Maintained by RBC Capital -- Price Target Lowered to $19.00 - GuruFocus
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Cuts Target Price to $19 - Moomoo
NUVB Maintained by Truist Securities -- Price Target Raised to $13.00 - GuruFocus
RBC Capital Adjusts Nuvation Bio Price Target to $19 From $20, Maintains Outperform Rating - marketscreener.com
Nuvation Bio raises $287.5M in convertible notes offering - Investing.com UK
Nuvation Bio raises $287.5M in convertible notes offering By Investing.com - Investing.com South Africa
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering - PR Newswire
Price to earnings forward of Nuvation Bio Inc. – NYSE:NUVB - TradingView
Inventory turnover of Nuvation Bio, Inc. Class A – FWB:1E30 - TradingView
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
Nuvation Bio Inc. Bonds — Corporate Bond Rates - TradingView
Does Nuvation Bio’s (NUVB) U.K. Taletrectinib Milestone Hint at Durable Global Oncology Positioning? - Sahm
Is Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative? - Yahoo Finance
Is Nuvation Bio (NYSE:NUVB) Building A Global Cancer Franchise? - Kalkine Media
Doctor-turned-dealmaker reveals his M&A playbook - Pharma Voice
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc - The National Law Review
Nuvation Bio Announces $200 Million Convertible Senior Notes Offering to Repay Debt and Fund Growth Initiatives - Minichart
Nuvation Bio Prices $250 Million 0.75% Convertible Notes Due 2032, Repays $58.5 Million Loan - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Wedbush Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale? - The Motley Fool
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale? - The Motley Fool
MHRA validates Nuvation Bio’s taletrectinib application in UK - Investing.com UK
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell 2000 Value Benchmark - marketscreener.com
Nuvation Bio's Taletrectinib Enters UK Regulatory Review - Moomoo
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
MHRA validates Nuvation Bio’s taletrectinib application in UK By Investing.com - Investing.com Nigeria
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom - PR Newswire
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell 3000E Value Benchmark - marketscreener.com
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Nuvation Bio prices $250M convertible notes offering - MSN
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes - Rockdale Citizen
Nuvation Bio, Inc. Class A Actuals & Estimates (NYSE:NUVB) - TradingView
Nuvation Bio prices $250M convertible notes offering By Investing.com - Investing.com Canada
Nuvation Bio Announces Proposed Convertible Senior Notes Offering - Investing News Network
NUVB Stock Builds Momentum As Charts And Cash Position Strengthen - StocksToTrade
Why is Nuvation Bio stock sliding today? - Investing.com
2.64%
大文字化:
|
ボリューム (24 時間):